In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
We have determined the in vitro activities of amphotericin B (AMB), voriconazole, posaconazole (PSC), itraconazole (ITC), ravuconazole, terbinafine, and caspofungin against five strains of Cunninghamella bertholletiae and four of Cunninghamella echinulata. The best activity was shown by terbinafine against both species (MIC range = 0.3 to 0.6 μg/ml) and PSC against Cunninghamella bertholletiae (MIC = 0.5 μg/ml). We have also evaluated the efficacies of PSC, ITC, and AMB in neutropenic and diabetic murine models of disseminated infection by Cunninghamella bertholletiae. PSC at 40, 60, or 80 mg/kg of body weight/day was as effective as AMB at 0.8 mg/kg/day in prolonging survival and reducing the fungal tissue burden in neutropenic mice. PSC at 80 mg/kg/day was more effective than AMB at 0.8 mg/kg/day in reducing the fungal load in brain and lung of diabetic mice. Histological studies revealed an absence of fungal elements in organs of mice treated with either AMB at 0.8 mg/kg/day or PSC at 60 or 80 mg/kg/day in both models. ITC showed limited efficacy in both models. PSC could be a therapeutic option for the treatment of systemic infections caused by Cunninghamella bertholletiae.
Pastor
F Javier
FJ
Unitat de Microbiologia, Facultat de Medicina, Universitat Rovira i Virgili, Carrer Sant Llorenç. 21, Reus, Spain.
Ruíz-Cendoya
Mery
M
Pujol
Isabel
I
Mayayo
Emilio
E
Sutton
Deanna A
DA
Guarro
Josep
J
D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000077336:Caspofungin; D020093:Cunninghamella / Q000187:drug effects* / Q000472:pathogenicity; D003921:Diabetes Mellitus, Experimental; D054714:Echinocandins / Q000494:pharmacology / Q000627:therapeutic use; D017964:Itraconazole / Q000494:pharmacology / Q000627:therapeutic use; D055666:Lipopeptides; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D013844:Thiazoles; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B; C104066:ER 30346; D000077336:Caspofungin; D065819:Voriconazole
Mycopathologia. 2008 Jun;165(6):407-10
18340546
Hippokratia. 2008 Jan;12(1):43-5
18923760
Antimicrob Agents Chemother. 2007 Jul;51(7):2587-90
17452481
Antimicrob Agents Chemother. 2009 Apr;53(4):1686-9
19171801
Infect Immun. 2008 Sep;76(9):4290-8
18644886
Clin Infect Dis. 2006 Apr 1;42(7):e61-5
16511748
Antimicrob Agents Chemother. 2006 Jan;50(1):126-33
16377677
Mycopathologia. 2006 Jan;161(1):33-5
16389482
Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2
12069997
J Pediatr Hematol Oncol. 2010 Mar;32(2):85-7
20118813
Clin Microbiol Rev. 2000 Apr;13(2):236-301
10756000
Eur J Clin Microbiol Infect Dis. 2006 Apr;25(4):215-29
16568297
Diagn Microbiol Infect Dis. 2004 Dec;50(4):247-51
15582297
J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i35-40
18063603
Antimicrob Agents Chemother. 2003 Nov;47(11):3647-50
14576138
J Clin Microbiol. 2009 Jun;47(6):1650-6
19386856
Mycopathologia. 1998-1999;144(3):141-6
10531680
Antimicrob Agents Chemother. 2003 Oct;47(10):3343-4
14506054
Antimicrob Agents Chemother. 2009 Feb;53(2):772-5
18936190
Clin Infect Dis. 2005 Sep 1;41(5):634-53
16080086
Ann Thorac Surg. 2006 Jul;82(1):338-40
16798251